Retatrutide: The Triple Agonist

The short version

Retatrutide (also known by its development code LY3437943) is an investigational drug, developed by Eli Lilly, that agonizes three receptors at once: GIP, GLP-1, and the glucagon receptor. It is not approved by the FDA or any regulatory agency as of mid-2026. It is in Phase 3 clinical trials.

The Phase 2 data are striking. In a 48-week obesity trial, retatrutide at 12 mg produced a mean -24.2% body-weight change versus -2.1% with placebo ^[20]. In a 36-week Phase 2 type 2 diabetes trial, it lowered HbA1c by -2.02% at 24 weeks and body weight by -16.94% at 36 weeks ^[21]. A Phase 2 liver-disease substudy found -82.4% relative reduction in liver fat at 24 weeks with 86% of participants reaching normal (<5%) liver fat ^[19]. These are Phase 2 numbers, not Phase 3, and they come from trials, not approved-product data.

A note on terminology: "GLP-3" is a misnomer sometimes applied to retatrutide — no such receptor class exists. The correct framing is GIP/GLP-1/glucagon triple agonist. This desk uses that framing throughout.

What it is

Retatrutide is a synthetic 39-amino-acid peptide built on a GIP-based backbone, acylated with a C20 fatty diacid for albumin binding and extended half-life enabling once-weekly dosing. Its molecular formula (free acid) is C221H342N46O68.

The compound was designed to add glucagon receptor (GCGR) agonism to the dual GIP/GLP-1 platform that tirzepatide pioneered — the logic being that controlled glucagon receptor activation increases energy expenditure and lipid mobilization, potentially amplifying weight loss beyond what the incretin axes alone can achieve. Structural confirmation of the triple-receptor engagement came from cryo-EM studies that resolved retatrutide's binding to GLP-1R, GIPR, and GCGR at near-atomic resolution (2.68/3.26/2.84 Angstrom) ^[18]. Its relative potency versus native hormones: approximately 8.9x at GIPR, 0.3x at GCGR, 0.4x at GLP-1R — a profile designed to harvest glucagon's metabolic benefits while minimizing the glucose-raising risk of full glucagon receptor engagement.

How it works

The mechanism is the sum of three receptor arms:

• GLP-1 receptor: Glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression from alpha cells, delayed gastric emptying, and central appetite suppression via hypothalamic circuits. The foundational incretin mechanism shared with semaglutide and tirzepatide.
• GIP receptor: Enhanced insulin sensitization, additional appetite modulation. The second axis that tirzepatide also engages.
• Glucagon receptor: Increased hepatic glucose output (mechanistically offset by the GLP-1/GIP insulin-augmenting arms), energy expenditure increase through thermogenic and lipid-oxidation pathways, and lipid mobilization from adipose tissue. This is the addition that distinguishes retatrutide from the dual agonists and is the proposed mechanism behind its larger weight-loss figures.

The glucagon arm is also responsible for the dose-dependent heart-rate increase documented in Phase 2. Glucagon receptor activation drives cardiac chronotropy (faster heartbeat) via cAMP/PKA signaling — a mechanism confirmed in isolated atrial preparations and tracked in the Phase 2 trial as mean heart-rate increases of approximately 5-7 bpm at the highest doses, peaking around 24 weeks ^[20][17].

What the research shows

Phase 2 obesity trial (n=338, 48 weeks, 2023). Once-weekly retatrutide at 12 mg produced mean body-weight change of -24.2% versus -2.1% with placebo. GI adverse events were dose-related and mostly mild to moderate; a dose-dependent heart-rate increase peaked around 24 weeks ^[20].

Phase 2 type 2 diabetes trial (n=281, 36 weeks, 2023). Retatrutide 12 mg lowered HbA1c by -2.02% at 24 weeks (versus -0.01% placebo) and reduced body weight by -16.94% at 36 weeks (versus -3.00% placebo). Mild-to-moderate GI adverse events in 35%; no severe hypoglycemia, no deaths ^[21].

MASLD liver-fat substudy (n=98, 48 weeks, 2024). In adults with obesity or overweight and metabolic dysfunction-associated steatotic liver disease (MASLD, ≥10% liver fat), retatrutide 12 mg reduced liver fat by -82.4% relative at 24 weeks, with 86% of participants reaching normal (<5%) liver fat. Reductions were sustained to 48 weeks (-86.0% at 12 mg) ^[19].

Structural mechanism (in vitro, 2024). Cryo-EM resolved retatrutide's simultaneous engagement of all three receptors. The structural work explained the relative potency profile (8.9x GIPR, 0.3x GCGR, 0.4x GLP-1R vs native hormones) and identified a conformational difference in how the extracellular loop 1 (ECL1) interacts with each receptor ^[18].

2025 pharmacology review. A 2025 Biomolecules review synthesized retatrutide's pharmacology and Phase 1/2 data, characterizing the up-to ~24% weight loss as a step-change versus prior incretin therapies and describing the ongoing Phase 3 (TRIUMPH) program ^[17].

Reported effects, cautions and safety

Anecdotal community reports (not clinical evidence, not verified): People using retatrutide in research-use contexts describe near-total silencing of food-related thoughts — described as a disinterest in eating rather than active satiety, more pronounced than experiences with GLP-1-class compounds. Rapid and noticeable weight reduction, often described as qualitatively faster than with prior compounds. A warmth or mild flushing sensation widely attributed in community discussion to the glucagon receptor arm's thermogenic effects. Reports of noticing elevated pulse — particularly in the hours after administration — some describe 5-15 bpm elevations above baseline on wearable devices, which maps to the Phase 2 heart-rate signal. GI discomfort, especially nausea peaking 4-8 hours post-administration and most pronounced during the first weeks. Sulfur burps, constipation, and early fatigue are also described. These are anecdotal, not clinical evidence — self-reports from research-use communities with no verified doses or clinical oversight.

Clinical-trial and regulatory-based cautions:

• Unapproved investigational compound: Retatrutide has no FDA approval. Gray-market material cannot be verified for identity, purity, or sterility. The FDA issued over 50 warning letters to retatrutide vendors in 2025 citing Federal FD&C Act violations.
• Dose-dependent GI adverse events: Nausea affected up to 45% of participants at the highest Phase 2 dose; the principal driver of 18% discontinuation at that dose. No dose-escalation oversight exists outside a clinical trial.
• Dose-dependent heart-rate increase: Phase 2 data show mean 5-7 bpm elevations peaking around 24 weeks, driven by glucagon receptor chronotropy ^[20]. A dedicated cardiovascular outcomes trial (NCT06383390) is ongoing; long-term cardiac effects are unknown.
• Lean-mass loss: Phase 2 body-composition data confirm retatrutide reduces lean mass alongside fat mass, raising sarcopenia concerns during rapid weight loss.
• Long-term unknowns: The TRIUMPH-1/2/3 Phase 3 series and dedicated cardiovascular/kidney outcome trials are ongoing as of mid-2026. No long-term outcomes data exist.
• Weight regain after stopping: Based on the pattern of GLP-1 class agents, substantial regain is expected after discontinuation.

Where it fits

Retatrutide sits on the investigational tier of this desk's spectrum — below the three approved compounds (semaglutide, tirzepatide, tesamorelin) and far above the preclinical compound (BPC-157) in terms of human evidence. Its Phase 2 data are the most impressive weight-loss numbers in any clinical trial of an incretin-class compound to date, but Phase 2 is not Phase 3, and Phase 3 is not approval.

The compound's place in the evidence hierarchy will change when Phase 3 trial data are published and when (if) regulatory approval is granted. Until then, it sits where it sits: well-characterized mechanistically, promising but unproven at scale, and genuinely unavailable as a verified product outside clinical trials.

For the comparison against all five compounds, see the evidence map.